Patients with dementia with Lewy bodies copy the interlocking pentagons on the mini-mental state examination less accurately than patients with Alzheimer disease

2000 ◽  
Vol 21 ◽  
pp. 83
Author(s):  
Thomas A. Ala ◽  
Larry F. Hughes ◽  
Greg A. Kyrouac ◽  
Mona W. Ghobrial ◽  
Rodger J. Elble
Keyword(s):  
Alzheimer Disease ◽  
Mental State ◽  
Dementia With Lewy Bodies ◽  
Mini Mental State Examination ◽  
Lewy Bodies ◽  
State Examination

Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer's disease, and normal participants in Taiwan

2013 ◽  
Vol 25 (11) ◽  
pp. 1839-1848 ◽  
Author(s):  
Carol Sheei-Meei Wang ◽  
Ming-Chyi Pai ◽  
Pai-Lien Chen ◽  
Nien-Tsen Hou ◽  
Pei-Fang Chien ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mental State ◽  
Cognitive Assessment ◽  
Dementia With Lewy Bodies ◽  
Mini Mental State Examination ◽  
Lewy Bodies ◽  
Montreal Cognitive Assessment ◽  
Operating Characteristics ◽  
State Examination

ABSTRACTBackground:The aim of this study was to examine and test the sensitivity, specificity, and threshold scores of the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE) and determine those that best correspond to a clinical diagnosis of dementia with Lewy bodies (DLB).Methods:Sixty-seven Alzheimer's disease (AD), 36 DLB, and 62 healthy participants without dementia (NC), aged 60 to 90, were enrolled. All three groups took the MoCA and MMSE tests at the same time. The Cochran–Mantel–Haenszel tests and receiver operating characteristics curve analysis were used to compare the different neuropsychological test results among the groups.Results:The cut-off point of the MoCA for AD was 21/22 with a sensitivity of 95.5% and a specificity of 82.3% (area under the curve (AUC): 0.945), and the cut-off point for DLB was 22/23 with a sensitivity of 91.7% and a specificity of 80.6% (AUC: 0.932). For the MMSE, the cut-off points for AD and for DLB from NC were all 24/25, with a sensitivity of 88.1% and a specificity of 85.5% for AD (AUC: 0.92), and a sensitivity of 77.8% and a specificity of 85.5% for DLB (AUC: 0.895). After controlling sex, age, and education, AD and DLB had lower scores in all MoCA subscales than the NC group (p < 0.05), except for the orientation and naming in DLB. In addition, AD had a lower score in the MoCA orientation (p = 0.03) and short-term memory (p = 0.02) than did DLB.Conclusions:The MoCA is a more sensitive instrument than the MMSE to screen AD or DLB patients from non-dementia cases.

scholarly journals Mini-Mental State Examination: Avaliação dos Novos Dados Normativos no Rastreio e Diagnóstico do Défice Cognitivo

2016 ◽  
Vol 29 (4) ◽  
pp. 240 ◽  
Author(s):  
Isabel Santana ◽  
Diana Duro ◽  
Raquel Lemos ◽  
Vanessa Costa ◽  
Miguel Pereira ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Mental State ◽  
Dementia With Lewy Bodies ◽  
Normative Data ◽  
Mini Mental State Examination ◽  
Lewy Bodies ◽  
State Examination

<p><strong>Introduction:</strong> The Mini-Mental State Examination is the most commonly used cognitive screening test. In Portugal, the cut-off scores are defined according to literacy groups, but different proposals have been recommended by more representative studies. We therefore propose to confirm the influence of demographical variables, such as age and education, in the subject’s performance; evaluating the discriminant ability of the new normative data; and to further examine the diagnostic acuity of the validated cut-off scoring for mild cognitive impairment and for the most prevalent types of dementia.<br /><strong>Material and Methods:</strong> Our study includes 1 441 educated subjects, divided into seven subgroups: Mild cognitive impairment, Alzheimer’s disease, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, community-controls and memory clinic-controls.<br /><strong>Results:</strong> Altogether age and education explain 10.4% of the Mini-Mental State Examination results variance, with both variables contributing significantly to the results’ prediction. The diagnostic acuity based on the most recent normative data was always higher than the one obtained through the validation cut-off scoring, revealing an overall excellent specificity (superior to 90%) and different sensitivity values: excellent for mild Alzheimer’s disease (91%), good for dementia with Lewy Bodies (78%) and low for mild cognitive impairment (65%), frontotemporal dementia and vascular dementia (55%).<br /><strong>Discussion and Conclusions:</strong> The performance on the Mini-Mental State Examination is influenced by age and education, supporting the use of normative data that consider those variables. With this approach, the Mini-Mental State Examination could be a sensitive and specific instrument for the Alzheimer’s disease screening among all healthcare levels. Nevertheless, its diagnostic acuity is limited in other conditions frequently seen in memory clinics, such as Mild Cognitive Impairment and other types of dementia.</p>

Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial

2001 ◽  
Vol 13 (2) ◽  
pp. 199-205 ◽  
Author(s):  
Janet Grace ◽  
Sarah Daniel ◽  
Timothy Stevens ◽  
K. K. Shankar ◽  
Zuzanna Walker ◽  
...  
Keyword(s):  
Dementia With Lewy Bodies ◽  
Mini Mental State Examination ◽  
Neuropsychiatric Symptoms ◽  
Lewy Bodies ◽  
Neuropsychiatric Inventory ◽  
Short Term ◽  
Open Label ◽  
Open Label Trial ◽  
State Examination

Patients with dementia with lewy bodies (DLB) have progressive deficits in cognition, parkinsonism, and neuropsychiatric symptoms. Cholinesterase inhibitors have been used to ameliorate cognitive decline and neuropsychiatric symptoms in short-term trials. In this study, patients with DLB were treated with rivastigmine up to 96 weeks. Improvement from baseline was seen in cognitive function as measured by the Mini-Mental State Examination (MMSE), and neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) over the first 24 weeks of treatment. By 96 weeks, neither the MMSE scores nor the NPI scores were significantly worse than at baseline.

scholarly journals Atrial fibrillation, antithrombotic treatment, and cognitive aging

Neurology ◽  
2018 ◽  
Vol 91 (19) ◽  
pp. e1732-e1740 ◽  
Author(s):  
Mozhu Ding ◽  
Laura Fratiglioni ◽  
Kristina Johnell ◽  
Giola Santoni ◽  
Johan Fastbom ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Alzheimer Disease ◽  
Cognitive Decline ◽  
Mental State ◽  
Mini Mental State Examination ◽  
National Study ◽  
Antithrombotic Treatment ◽  
Increased Risk ◽  
Anticoagulant Drugs ◽  
State Examination

ObjectiveTo examine the association of atrial fibrillation (AF) with cognitive decline and dementia in old age, and to explore the cognitive benefit of antithrombotic treatment in patients with AF.MethodsThis population-based cohort study included 2,685 dementia-free participants from the Swedish National Study on Aging and Care in Kungsholmen, who were regularly examined from 2001–2004 to 2010–2013. AF was ascertained from clinical examination, ECG, and patient registry. Global cognitive function was assessed using the Mini-Mental State Examination. We followed the DSM-IV criteria for the diagnosis of dementia, the NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences) criteria for vascular dementia, and the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria for Alzheimer disease. Data were analyzed using multiple linear mixed-effects and Cox regression models.ResultsWe identified 243 participants (9.1%) with AF at baseline. During the 9-year follow-up period, 279 participants (11.4%) developed AF and 399 (14.9%) developed dementia. As a time-varying variable, AF was significantly associated with a faster annual Mini-Mental State Examination decline (β coefficient = −0.24, 95% confidence interval [CI]: −0.31 to −0.16) and an increased hazard ratio (HR) of all-cause dementia (HR = 1.40, 95% CI: 1.11–1.77) and vascular and mixed dementia (HR = 1.88, 95% CI: 1.09–3.23), but not Alzheimer disease (HR = 1.33, 95% CI: 0.92–1.94). Among people with either prevalent or incident AF, use of anticoagulant drugs, but not antiplatelet treatment, was associated with a 60% decreased risk of dementia (HR = 0.40, 95% CI: 0.18–0.92).ConclusionAF is associated with a faster global cognitive decline and an increased risk of dementia in older people. Use of anticoagulant drugs may reduce dementia risk in patients with AF.

Sign in / Sign up

Export Citation Format

Share Document